TL;DR
- •Spravato (esketamine) is the S-isomer of ketamine, FDA-approved as an intranasal spray for treatment-resistant depression and depression with active suicidal ideation.
- •Generic ketamine is racemic (50% R + 50% S enantiomer) and is used off-label for depression by physicians experienced in mood-disorder treatment — same NMDA mechanism, different molecular composition.
- •Spravato requires in-clinic administration at a REMS-certified facility with 2-hour post-dose monitoring. Sublingual ketamine can be administered at home under physician supervision.
- •Cost: Spravato is typically $590-980 per session even with insurance ($800+ out-of-pocket without). Tovani's sublingual ketamine is $349/month including unlimited sessions in the maintenance phase.
- •Efficacy: head-to-head trials suggest comparable response rates, though some studies show advantage for IV racemic ketamine over Spravato. The R-isomer may contribute meaningfully to antidepressant effect.
- •Both work through NMDA antagonism. For most treatment-resistant patients, the practical choice is cost + access (sublingual ketamine) vs insurance-covered + in-clinic (Spravato).
Side by side
Ketamine
Racemic ketamine (R + S enantiomers)
NMDA-receptor antagonist (off-label for depression)
What it treats
Off-label: treatment-resistant depression, anxiety, PTSD, chronic pain, FDA-approved: anesthesia, surgical sedation
Mechanism
NMDA-receptor antagonism producing acute glutamate surge, BDNF-mediated synaptic plasticity, and rapid antidepressant effects. Contains both R and S enantiomers — R may contribute meaningfully alongside the S-isomer Spravato uses exclusively.
Strengths
- •Sublingual at-home administration option (Tovani, telehealth)
- •Lower cost — $349/month at Tovani vs $5000+/year for Spravato
- •Same physician every visit (continuity)
- •No insurance preauthorization gauntlet
Limitations
- •Off-label use — not FDA-approved specifically for depression
- •Not covered by insurance (direct-pay model)
- •Patient must be screened for safety (cardiovascular, psychiatric history)
- •Quality varies between providers — physician training matters
Spravato
Esketamine (S-isomer)
NMDA-receptor antagonist (FDA-approved)
What it treats
Treatment-resistant depression (failure of 2+ antidepressants), Major depression with active suicidal ideation/behavior
Mechanism
Pure S-enantiomer of ketamine. NMDA-receptor antagonism producing similar rapid antidepressant effect as racemic ketamine. Intranasal route avoids first-pass metabolism.
Strengths
- •FDA-approved specifically for depression (clinical legitimacy)
- •Insurance coverage available (with prior authorization)
- •Strict REMS protocol provides safety standardization
- •Strongest formal evidence base in TRD trials
Limitations
- •In-clinic only — 2-hour monitoring required per session
- •High cost even with insurance ($590-980 per session typical)
- •Insurance prior-auth burden (multiple denied antidepressants required)
- •Travel + appointment time burden (twice-weekly induction phase)
Which one for your situation?
If:
Insurance covers Spravato AND you can do in-clinic 2x/week for 4 weeks
Verdict:
Spravato — covered, FDA-approved, formal protocol
If:
Insurance won't cover Spravato OR you can't do in-clinic scheduling
Verdict:
Sublingual ketamine — same mechanism, lower cost, at-home
If:
Want maximum privacy from insurance records
Verdict:
Sublingual ketamine (direct-pay, no insurance claim)
If:
Active suicidal ideation requiring rapid intervention
Verdict:
Either — Spravato has the FDA approval for this indication; sublingual ketamine with experienced physician has similar rapid effect
If:
Want regular physician relationship through treatment
Verdict:
Sublingual ketamine — same physician every session at Tovani vs rotating panel at typical Spravato clinics
If:
Have access to both — pure clinical-efficacy comparison
Verdict:
Comparable in published trials, with some advantage for racemic in head-to-head studies. Convenience and cost differentiate more than efficacy.
Where ketamine fits
Tovani provides sublingual at-home ketamine therapy with physician-led telehealth consultation in Florida and New Jersey. The model fits patients who want the NMDA mechanism without the in-clinic burden, insurance friction, or per-session cost structure of Spravato.
Both Spravato and sublingual ketamine produce mood response within hours-to-days of the first session. Spravato's formal protocol is twice-weekly for 4 weeks (induction), then weekly to bi-weekly maintenance. Sublingual ketamine flexes around patient response and life schedule.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Is Spravato just the same as ketamine?
Same mechanism (NMDA-receptor antagonism), different molecule. Spravato is pure S-enantiomer; generic ketamine is racemic (R + S mix). Some studies suggest the R-enantiomer contributes to antidepressant effect, which is why some clinicians prefer racemic. Both produce rapid mood improvement.
Why is Spravato so expensive?
Spravato is a patented branded medication; racemic ketamine has been generic for decades. Insurance coverage exists but typically requires multiple documented antidepressant failures and prior authorization. Out-of-pocket costs of $800+ per session are common when not covered. Sublingual ketamine is direct-pay but at a fraction of the per-session cost.
Can I do Tovani if my insurance covers Spravato?
Yes. The Tovani model is direct-pay regardless of insurance status. Many patients choose Tovani over their insurance-covered Spravato because the at-home model fits their life better, even though Spravato would cost less out-of-pocket. Others use Spravato through insurance until they can't maintain the schedule, then switch to maintenance with Tovani.
Which is safer?
Both have established safety profiles in their respective protocols. Spravato's in-clinic requirement provides one layer of standardization. Sublingual ketamine's safety depends on physician screening and protocol — Tovani screens for cardiovascular risk, bipolar disorder, dissociation history, and other factors before starting. For a healthy candidate, both routes are well-tolerated.
Will the R-enantiomer in racemic ketamine cause more side effects?
Mild dissociation is a feature of NMDA antagonism with both formulations. Some research suggests R-ketamine may be longer-lasting and produce less acute dissociation per dose, but evidence is still emerging. In clinical practice, both Spravato and racemic ketamine are tolerated comparably by most patients.
References
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — 64% response vs 28% placebo. The reference trial that established ketamine's antidepressant effect; led directly to Spravato development. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — addresses racemic vs esketamine differences and clinical-context guidance for both. PMID 28249076